Qiagen plots another diagnostics buyout deal

Qiagen CFO Roland Sackers tells Bloomberg that the diagnostics company is in the hunt for a new acquisition that would register in the "three-digit million dollar range." The Dutch company has been on a buyout spree in recent years as it snaps up other diagnostic players around the world. Qiagen acquired Digene in 2007 for $1.6 billion. "The focus on our acquisitions side is clearly on content, adding more tests to the machines in the field of molecular diagnostics, but also in the field of applied testing," Sackers told the business news service. Report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.